Stentit
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Stentit - overview
Established
2017
Location
Eindhoven, -, Netherlands
Primary Industry
Biopolymers
About
Based in Eindhoven, Netherlands, and co-founded in 2017 by BART SANDERS, Stentit B. V. , dba Stentit, is a regenerative medical devices manufacturer for cardio-related issues. In April 2022, Stentit B.
V. , led by its CEO Bart Sanders, raised EUR 1. 8 million in seed funding from new investors NextGen Ventures, BOM Brabant Ventures, and the Ten Cate Investeringsmaatschappij. The company provides a healthcare platform offering solutions for endovascular treatment based on regenerative stent technology supporting patients suffering from cardiovascular diseases.
The company intends to use the funds raised in April 2022 to expand the development and manufacturing of regenerative stents for peripheral applications.
Current Investors
NextGen Ventures, BOM Brabant Ventures, Ten Cate Investeringsmaatschappij
Primary Industry
Biopolymers
Sub Industries
Biopolymers, Cardiology, Medical Equipment Distributors, Biomaterials
Website
www.stentit.com
Verticals
Manufacturing
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.